scholarly article | Q13442814 |
P50 | author | C. Ronald Kahn | Q16106681 |
Siegfried Ussar | Q43108049 | ||
P2093 | author name string | Sara G Vienberg | |
P2860 | cites work | Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21 | Q24318639 |
FGF-21 as a novel metabolic regulator | Q24523933 | ||
Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State | Q24625976 | ||
New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure | Q24652521 | ||
Fibroblast growth factor 21: from pharmacology to physiology | Q24658126 | ||
Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level | Q28237301 | ||
Cell-surface co-receptors: emerging roles in signaling and human disease | Q30039645 | ||
Cellular bioenergetics as a target for obesity therapy | Q33894407 | ||
Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats | Q33930333 | ||
Enterovirus RNA in blood is linked to the development of type 1 diabetes | Q34448707 | ||
Extracellular interactome of the FGF receptor-ligand system: complexities and the relative simplicity of the worm | Q37318049 | ||
TSH receptor autoantibodies | Q37426868 | ||
FGF21: a novel prospect for the treatment of metabolic diseases. | Q37428992 | ||
Autoimmune disorders of the neuromuscular junction | Q37475932 | ||
Physiological inhibitors of Wnt signaling | Q37845920 | ||
Fibroblast growth factors and their receptors in cancer | Q37895306 | ||
Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. | Q39427414 | ||
Receptors, Antireceptor Antibodies and Mechanisms of Insulin Resistance | Q39783501 | ||
Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. | Q40508811 | ||
Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia | Q43282888 | ||
Overexpression of the insulin receptor inhibitor PC-1/ENPP1 induces insulin resistance and hyperglycemia | Q43986109 | ||
P433 | issue | 113 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 113ps47 | |
P577 | publication date | 2011-12-01 | |
P1433 | published in | Science Translational Medicine | Q1573955 |
P1476 | title | Receptor antibodies as novel therapeutics for diabetes | |
P478 | volume | 3 |
Q40311070 | A Novel Allosteric Insulin Receptor-Activating Antibody Reduces Hyperglycemia without Hypoglycemia in Diabetic Cynomolgus Monkeys |
Q41161575 | Acute Treatment With XMetA Activates Hepatic Insulin Receptors and Lowers Blood Glucose in Normal Mice. |
Q36058468 | An allosteric antibody to the leptin receptor reduces body weight and reverses the diabetic phenotype in the Lep(ob) /Lep(ob) mouse |
Q36620162 | Epitope-specificity of recombinant antibodies reveals promiscuous peptide-binding properties |
Q35095516 | Improved glucose metabolism in vitro and in vivo by an allosteric monoclonal antibody that increases insulin receptor binding affinity |
Q41966485 | Inhibition of insulin receptor function by a human, allosteric monoclonal antibody: a potential new approach for the treatment of hyperinsulinemic hypoglycemia. |
Q38215993 | Selective allosteric antibodies to the insulin receptor for the treatment of hyperglycemic and hypoglycemic disorders |
Q30234616 | The Role and Potential Therapeutic Implications of the Fibroblast Growth Factors in Energy Balance and Type 2 Diabetes |
Q38354696 | Theoretical and computational studies of peptides and receptors of the insulin family |
Q54468633 | Treating diabetes and obesity with an FGF21-mimetic antibody activating the βKlotho/FGFR1c receptor complex. |
Q51350644 | XMetA, an allosteric monoclonal antibody to the insulin receptor, improves glycaemic control in mice with diet-induced obesity. |
Search more.